MGI alum garner $60M to launch new cancer drug developer

A group of MGI Pharma alumni is launching a Boston-based startup named Tesaro in Boston with $60 million in venture backing for its plan to acquire, develop and commercialize new cancer drugs. The company is being co-founded and partially financed by a core of execs coming from MGI--by way of Abraxis--which was acquired by Eisai in 2008 for $3.9 billion. The team: Lonnie Moulder, chief executive officer; Mary Lynne Hedley, Ph.D., president and chief scientific officer; and Rick Rodgers,...